Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adjacent, adjunct, Alpha, Ambassador, article, articulated, assumption, AthelosTM, auditor, BA, behavior, behavioral, beta, Biopharma, blackberry, Bluestone, bona, breakthrough, breathing, calender, Capricor, cardiologist, cast, CDC, cGCP, chance, Chicago, Chine, chosen, Citation, Clark, clause, clock, CMO, COMP, constriction, convey, COO, COSO, CTD, cystic, database, deferral, deliverability, Deloitte, depth, Devereux, dialogue, Dickey, dossier, doubling, dysfunction, earliest, editor, editorial, EEA, effector, Eileen, Eli, Elizabeth, emotional, erected, EU, Eurand, excessive, exocrine, FACP, FAHA, Farr, fatigue, fault, Feinberg, fell, fide, filer, Foell, fold, Francisco, freedom, fulfill, Glasgow, GlaxoSmithKline, guarantor, Hangzhou, Harmonization, HEB, Hemispherx, Herold, HR, Iceland, ICH, infant, inflammation, influenza, Inside, insulin, intrinsic, IPO, Janet, Jeffrey, juvenile, Kenexa, Kevan, League, Lehman, Liechtenstein, Lilly, LLCTM, LLY, Losordo, LP, MarksonHRC, meantime, mediated, Miami, mild, Miraca, motivate, NexMed, North, Northwestern, Norway, notable, Omega, onset, oral, OraPharma, orchestrate, organizational, OSCT, PC, pharmacovigilance, phone, pilot, PIP, polyclonally, Princeton, Protarga, PSCT, Qizhi, QP, QPPV, question, rata, regime, reissuance, remind, RMP, row, SA, Scholar, scientist, scleroderma, secrete, shape, simultaneously, sixteen, somatic, stayed, StemCyte, Student, surveyed, suspected, Suzhu, SVP, tactical, Tang, TBI, text, thousand, tier, traced, UCSF, unanimously, unblinded, undergone, unencumbered, unfair, unlicensed, unnecessary, unqualified, unsolicited, Valeant, Vermont, versa, viral, Visionary, week, whichever, women, XIDEQ, Zenpep
Removed:
abatement, acquire, amend, amex, annum, arrange, assert, asserted, attached, Australia, begun, bifurcated, Brown, Cambridge, campaign, carrier, Catholic, CDMRP, characterized, charitable, comparability, concept, conceptualize, Congressionally, consolidating, contemplated, convert, converted, corneal, cultural, cutting, David, distributor, dollar, extraction, feasibility, fifty, forma, Geehr, gradually, Graham, great, greatest, inclusive, initiative, interdisciplinary, invested, isolation, Japan, Keck, lab, liquidation, logistical, margin, Mariusz, marked, MD, mezzanine, Michigan, moderation, moral, myriad, nationalized, NOL, notification, NS, opposed, Parkinson, penetration, percent, philosophical, preserving, prevailing, PRMRP, prove, qualitative, quantitative, Ratajczak, ready, recombinant, reflecting, reflective, relevance, relieving, repaid, reportable, resale, revaluation, Rheumatology, Roger, salable, shift, show, solid, south, Southern, Subco, surviving, teaching, Telemedicine, theological, topically, unaudited, undistributed, usable, vast, Vatican, vitro, waive, waived, xi, xii, xiii
Filing tables
Filing exhibits
Related press release
LSTA similar filings
Filing view
External links
Exhibit 21.1
Subsidiaries of NeoStem, Inc.
Entity | Percentage of Ownership |
NeoStem, Inc. | ParentĀ Company |
NeoStem Therapies, Inc. | 100% |
Stem Cell Technologies, Inc. | 100% |
Amorcyte, LLC | 100% |
Progenitor Cell Therapy, LLC (PCT) | 100% |
NeoStem Family Storage, LLC | 100% |
Athelos Corporation (1) | 88.5% |
PCT Allendale, LLC | 100% |
(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of DecemberĀ 31, 2013, BD's ownership interest in Athelos was decreased to 11.5%, and our ownership increased to 88.5%. As a result in the change in ownership, approximately $0.3 million was transferred from additional paid in capital to non-controlling interests.